Seven years ago, before pharmacy e-vouchers became mainstream, we brought on a new client quickly started hearing complaints from members. Their out-of-pocket costs at the pharmacy counter had gone up, and in some cases, the increase was significant. From the member’s perspective, the new pharmacy benefit looked worse. They were not thinking about rebates, net cost, formulary intent, or the employer’s fiduciary responsibility. They only knew they were paying more than they had paid before.

When we reviewed the claims, the issue became clear. Under the prior arrangement, manufacturer assistance had been quietly reducing member copays through e-vouchers and coupon like programs. The savings made the prescription feel cheaper to the member, but the plan was often paying more because the voucher helped keep the patient on a higher-cost brand drug. The member liked the lower copay, the manufacturer protected the brand, and the transaction looked smooth at the pharmacy counter. The employer was left with the higher total cost.

That experience changed the way I looked at pharmacy e-vouchers. They are marketed as a patient affordability tool and sometimes they do help a patient fill a medication they might otherwise abandon. But for self-funded employers, the story is more complicated. A lower copay at the counter does not automatically mean a lower cost for the plan. In many cases, the e-voucher improves the member’s short term experience while weakening the employer’s ability to manage the pharmacy benefit in the long term interest of the plan.

What Pharmacy e-Vouchers Really Do

A pharmacy e-voucher is a manufacturer-funded discount delivered electronically during the prescription claims process. Unlike an old fashioned paper coupon or a copay card the member has to present, the e-voucher can be applied automatically. The member may not know why the cost dropped. The pharmacist may only see the claim response. The employer may not see the full transaction details unless its reporting specifically captures manufacturer assistance at the claim level.

The important point is where the voucher sits in the transaction. In many arrangements, manufacturers place e-vouchers through switch operators or claims routing infrastructure. That allows the voucher to be triggered inside the electronic pharmacy claim, often before the employer has a clear view of what happened. The pharmacy counter is no longer the control point. The discount can be embedded upstream in the claims process, which makes it easier for the manufacturer’s strategy to influence the final outcome without much visibility to the plan sponsor.

To the member, this feels like a benefit. A prescription that may have cost $100, $250, or more suddenly costs $25. The member leaves the pharmacy satisfied and any plan design meant to create cost awareness loses its impact. But the plan may still be paying a much higher amount than it would have paid for a preferred generic, biosimilar, therapeutic alternative, or lower net cost brand drug. The member sees the savings. The employer absorbs the economics behind the curtain.

When Copay Relief Becomes Cost Shifting

The dark side of e-vouchers is not the discount itself. The dark side is the way the discount can separate the member’s out-of-pocket cost from the plan’s total cost. Once those two numbers are disconnected, members naturally make decisions based on what they pay at the pharmacy counter. They do not have access to the plan’s net cost. They are not expected to run a fiduciary analysis before picking up a prescription. They respond to the price placed in front of them.

Manufacturers understand this better than anyone. E-vouchers are not random acts of generosity. They are market access tools designed to reduce prescription abandonment, protect brand utilization, and soften the effect of formulary controls. If a drug is placed on a non-preferred tier or faces competition from a lower cost alternative, an e-voucher can make the higher cost drug feel like the better deal to the patient. The manufacturer keeps the prescription. The member gets a lower copay. The plan may pay more.

This is where self-funded employers get hurt. Employers spend real money building formularies, prior authorization criteria, step therapy rules, tiered copays, and other plan design features. Those tools are not meant to create friction for the sake of friction. They are intended to guide members toward clinically appropriate, cost-effective therapy. When an e-voucher overrides the financial signal built into the plan design, it can quietly pull utilization in the opposite direction.

This also explains why members may push back when an employer moves to a more transparent, fiduciary model. If the prior arrangement allowed e-vouchers to reduce member copays on expensive drugs, the old plan may have felt better to the member even when it was worse for the employer. That creates a communication challenge. The employer may be improving governance and lowering total plan cost, while some members only see that they now pay more at the counter for certain brand drugs.

Why Employers Often Miss the Problem

Most employers do not receive enough detail to evaluate e-vouchers properly. Standard pharmacy reporting may show gross cost, ingredient cost, dispensing fee, member cost share, rebates, and total plan paid amounts. But it may not clearly show whether an e-voucher was used, how much manufacturer assistance was applied, whether the assistance counted toward the deductible or out-of-pocket maximum, and whether the claim supported or undermined formulary intent.

That lack of visibility is not a minor reporting gap. It prevents the plan sponsor from understanding who influenced the claim and who benefited from the transaction. The manufacturer may have used the voucher to keep the member on its brand. A switch, coupon processor, PBM, pharmacy, accumulator vendor, or other party may have earned a fee somewhere in the workflow. The member may have received short term relief. The employer may have paid a higher total cost without seeing the full chain of events.

The attached e-voucher workflow illustrates why this matters. Pharmacy claims can pass through multiple entities before the final patient cost and plan paid amount are determined. When manufacturer assistance is introduced into that process, especially through electronic routing, the employer needs claim level visibility to understand the financial effect. Without it, the plan sponsor cannot tell whether the e-voucher helped the plan, helped the member, helped the manufacturer, or simply moved money around in a way that made the benefit harder to manage.

This becomes even more complicated when e-vouchers interact with copay accumulator or maximizer programs. In some arrangements, manufacturer assistance lowers the member’s cost at the pharmacy but does not count toward the deductible or out-of-pocket maximum. The patient may feel protected early in the year, then face a much larger bill once the assistance is exhausted. In other arrangements, maximizer programs are designed to capture more manufacturer assistance for certain specialty drugs. These programs can reduce plan cost in specific cases, but only if the employer understands the fees, member impact, vendor incentives, and claim-level financial flow.

The Fiduciary Standard for e-Vouchers

A self-funded employer does not need to oppose every form of manufacturer assistance. That would be too simplistic. Some members rely on assistance to afford necessary medications, especially when plan designs create high out-of-pocket exposure. The better position is not to ban e-vouchers blindly, but to demand full disclosure and measure whether the arrangement serves the plan and its members.

The fiduciary test should be straightforward. If manufacturer dollars touch the pharmacy benefit, the employer should know. If an e-voucher changes the member’s copay, the employer should know. If a rejected claim is converted into a paid claim through a manufacturer funded pathway, the employer should know. If any vendor earns revenue from the transaction, the employer should know. Hidden money has no place in a fiduciary model.

Self-funded employers should ask direct questions:

1. Self-funded employers should ask direct questions:
2. Which claims used e-vouchers or electronic manufacturer assistance?
3. Which drugs and manufacturers were involved?
4. Did the e-voucher support a preferred or nonpreferred drug?
5. Did the assistance count toward the member’s deductible or out-of-pocket maximum?
6. Were any rejected claims converted into paid claims?
7. What fees were paid to the PBM, switch, coupon processor, pharmacy, or accumulator vendor?
8. Can the plan audit this data at the claim level?

These questions are not anti-member. They are responsible benefit governance. Employers should require reporting that identifies e-voucher use at the claim level. Without this detail, the employer cannot judge whether the voucher improved affordability or weakened the plan’s cost management strategy.

Consultants and brokers should also be careful when comparing pharmacy benefit arrangements based only on member disruption. A plan that allows hidden e-vouchers may appear more member friendly in the short run, especially for people using high cost brand drugs. But if the plan is paying more to preserve those drugs, the employer deserves to know. Lower friction at the counter can come with a higher invoice behind the scenes.

The Bottom Line for Plan Sponsors

E-vouchers are attractive because they solve the problem members feel most directly: the cost they see at the pharmacy counter. But employers fund the benefit and their problem is broader. They must manage total drug spend, clinical appropriateness, vendor incentives, compliance risk, member affordability, and fiduciary oversight. Any program that improves one part of the experience while hiding the rest deserves scrutiny.

The most dangerous pharmacy benefit tools are not always the ones that look expensive. Sometimes, they are the ones that look helpful. E-vouchers can make a high-cost drug feel affordable while allowing the underlying price problem to remain untouched. They can make members believe one plan is better than another based on copay alone. They can also make it harder for employers to implement a disciplined, lowest net cost pharmacy strategy.

Employers should not confuse a lower copay with a better deal. They should not assume manufacturer assistance is free money. And they should not allow any third party to influence plan design without full transparency.

A pharmacy benefit built under a fiduciary standard of care requires visibility into every dollar, every incentive, and every transaction pathway. E-vouchers may have a place, but only when the plan sponsor can see what they are doing. When the member sees the discount and the employer pays the higher bill, the benefit is not being managed transparently. It is being managed around the employer.

Most employers have never read the medication policies controlling high cost drug decisions inside their pharmacy benefit plan. Brokers, consultants, and Benefits Directors spend plenty of time reviewing rebates, discounts, formularies, guarantees, and specialty drug trend. Those items matter. But medication policies are where many day-to-day coverage decisions are actually made. If you have not reviewed these policies, you do not fully know how your pharmacy benefit is being managed.

A medication policy is a written clinical and coverage rule for a specific drug, drug class, or treatment category. It explains when a medication may be covered, what documentation is required, what alternative therapies must be tried first, how much of the drug may be dispensed, and how long the approval lasts. In plain English, it is the rulebook used to decide whether a prescription gets approved, denied, limited, or sent back for more information.

Medication policies are more than clinical paperwork. They are plan governance documents.

These policies matter because many high cost medications are not simple yes-or-no decisions. They involve diagnosis, disease severity, treatment history, FDA labeling, clinical guidelines, safety concerns, quantity limits, and plan-specific product preferences. A good medication policy brings those factors together in one place so decisions are consistent, defensible, and aligned with the plan sponsor’s intent.

Take migraine treatment as an example. Newer migraine therapies, including CGRP inhibitors, can be clinically appropriate for the right patients. They can also create unnecessary cost when used without proper criteria. A migraine medication policy may identify the drugs covered under the category, separate preferred from non-preferred products, and require prior authorization before approval.

For migraine prevention, the policy might require documentation that the member has had at least four migraine days per month for at least three months, has functional impairment, and has already tried guideline recommended preventive medications. For acute migraine treatment, the policy might require documented failure or contraindication to generic triptans before covering a newer, higher cost drug. This is not arbitrary cost control. When properly designed, it is evidence-based management.

A bad medication policy can block appropriate care, frustrate members, and create unnecessary provider abrasion. A good medication policy protects the member, the plan, and the employer. It helps ensure the right drug is used for the right patient, at the right time, for the right clinical reason.

Medication policies are usually created by a pharmacy benefit administrator, PBM, health plan, or delegated clinical team. The better ones are developed by pharmacists and clinicians who review FDA labeling, prescribing information, peer-reviewed literature, specialty society guidelines, safety data, and available therapeutic alternatives. Many are also reviewed by a Pharmacy and Therapeutics Committee, often called a P&T Committee, made up of physicians, pharmacists, and other clinical experts.

This is where the fiduciary issue comes in.

A medication policy should support the plan sponsor’s duty to manage the pharmacy benefit prudently and solely in the interest of the plan and its members. It should not quietly steer utilization toward products that are more profitable for the vendor. A policy can be written to encourage clinically appropriate, lower-net-cost therapy. It can also be written to favor drugs with better economics for the PBM. The employer may never see the difference unless someone asks.

Medication policies are most often used during prior authorization, step therapy, quantity limit review, formulary exception review, and reauthorization. When a prescriber submits a request for a drug requiring review, the clinical reviewer compares the request against the policy.

• Does the patient have the required diagnosis?
• Has the patient tried the required first-line therapies?
• Is the requested drug FDA-approved or supported by current guidelines?
• Is the quantity consistent with labeling and safe use? Is the medication preferred under the plan?
• Is there a lower-cost clinically appropriate alternative?

If the request meets the criteria, the drug may be approved. If not, the request may be denied or returned for more documentation. This process is not perfect and it should not be treated as a substitute for medical judgment. Providers still make clinical decisions. Medication policies are coverage tools. Their purpose is to help the plan apply consistent standards while allowing room for exceptions when properly supported.

Reauthorization is another important use. A drug may be reasonable to try, but that does not mean the plan should keep paying indefinitely if the member is not improving. For expensive therapies, reauthorization criteria often require updated progress notes or evidence of clinical benefit. In migraine, this could include fewer headache days, reduced use of rescue medications, fewer missed workdays, or improved ability to perform daily activities.

This is common sense plan management. If a medication is working, continued coverage may be appropriate. If it is not working, the plan should know.

Quantity limits serve a similar purpose. Some drugs have high cost exposure when use exceeds clinically appropriate limits. A policy may specify how many tablets, injections, syringes, pens, or devices are covered per month. These limits should be tied to FDA labeling, clinical evidence, and accepted practice patterns. They should not be random denial mechanisms.

For brokers and consultants, medication policies are a useful oversight tool. They show how the pharmacy benefit actually functions behind the scenes. Advisors should request the policies for the top cost-driving categories, including GLP-1s, inflammatory conditions, migraine, oncology support drugs, fertility, hemophilia, multiple sclerosis, and rare disease therapies.

Then ask direct questions.

• Who wrote the policy?
• When was it last reviewed?
• What references support it?
• Who approved it?
• How are preferred products selected?
• Are lowest net cost options prioritized?
• How are exceptions handled?
• Does the policy align with the plan document?
• Are denial and appeal decisions being applied consistently?

Benefits Directors should ask these questions before implementation, not after an employee complaint. Learning the rules only after a member is denied care is a poor way to manage a pharmacy benefit plan. The larger point is simple. Medication policies reveal whether your plan is being managed with discipline, transparency, and accountability. They protect patients by grounding decisions in evidence. They protect the plan by reducing inappropriate utilization, unsafe use, and waste. They protect the employer by supporting consistent decisions under a fiduciary standard of care. If you have not reviewed them, you are trusting someone else’s rulebook without knowing what is in it.

Self-funded employers spend months negotiating pharmacy benefit terms, reviewing clinical programs, and selecting a pharmacy benefit manager, only to lose control once claims start processing. The contract may look good. The pricing may look competitive. The clinical strategy may sound reasonable. But if members are routinely filling non-formulary drugs, the plan is bleeding money. A formulary is only as good as the discipline behind it.

That is why formulary compliance matters.

Formulary compliance measures whether the drugs being paid for by the plan align with the plan’s approved drug list. In plain English, it answers a simple question: Are we paying for the drugs we agreed should be covered, or are we paying for exceptions, workarounds, and waste? A practical way to measure formulary compliance is to calculate non-formulary spend as a percentage of total net drug spend:

Formulary Compliance Rate (measured by non-formulary spend %) = non-formulary drug spend ÷ total net drug spend × 100

For this benchmark to be useful, “total net drug spend” must be defined consistently. Start with total allowed pharmacy cost, then subtract all credits that reduce the plan’s true cost, including rebates, drug-level credits, refunds, guarantees, reversals, adjustments, and other post-adjudication pharmacy credits returned to the plan. Copay assistance credits should only be included if the plan actually captures those dollars. Without a clear net spend definition, the non-formulary spend percentage can make compliance look better or worse than it really is.

For example, if a self-funded employer spends $10 million annually on prescription drugs and $250,000 is tied to approved non-formulary claims, the plan’s non-formulary spend rate is 2.5%. In most cases, 2% to 3% or less suggests the formulary is being followed and exceptions are being used appropriately. A rate between 3% and 5% deserves review. Anything above 5% should trigger a deeper audit of exception approvals, therapeutic classes, and whether the PBM or pharmacy benefit administrator is allowing the P&T committee’s work to be bypassed.

This gives HR, finance, and benefits consultants a clean starting point. You can also track the number of non-formulary claims, the number of members using non-formulary medications, and the top therapeutic classes driving the spend. But the dollar impact should come first because that is what reveals whether the issue is material. A strong compliance report should show three things:

1. Total formulary drug spend
2. Total non-formulary drug spend
3. The reason non-formulary claims were approved

Without the reason codes, the report is incomplete. Some exceptions are clinically appropriate. Others are just poor plan management. Good compliance does not mean zero exceptions. That is unrealistic and, in some cases, inappropriate. Good compliance means the plan has a clear formulary, a fair exception process, and a low level of non-formulary spend that can be explained.

Another example, suppose a self-funded employer spends $10 million annually on prescription drugs. If $350,000 is non-formulary spend, that may be acceptable if most of it is tied to documented clinical exceptions, failed step therapy, or continuity-of-care decisions. But if $1.5 million is going to non-formulary drugs with no clear documentation, no prior authorization history, and no therapeutic rationale, that is not member advocacy. That is plan leakage.

This is where the Pharmacy and Therapeutics committee, commonly called the P&T committee, becomes critical. A formulary should not be built by sales teams, rebate departments, account managers, or anyone else with a financial interest in which drugs win preferred placement. It should be built through a clinical review process led by qualified, conflict-free professionals who evaluate safety, efficacy, therapeutic value, and appropriate alternatives.

The most efficient way to measure formulary compliance is to monitor non-formulary spend as a percentage of total net drug spend.

When the P&T committee does its job well, the formulary has clinical credibility. It gives the plan sponsor a defensible basis for coverage decisions. It also helps separate legitimate clinical exceptions from financial manipulation. The problem starts when the work of the P&T committee is circumvented after the fact.

This can happen when non-formulary drugs are routinely approved without documented clinical justification, when rebate arrangements override clinical recommendations, or when “special handling” is used to keep certain high-cost drugs flowing through the plan. Once that happens, the formulary becomes a suggestion instead of a standard.

For self-funded employers, that is dangerous. The plan sponsor may believe it has adopted a clinically sound formulary, while the actual claims experience tells a different story. A fiduciary standard of care requires the employer to know whether the formulary is being followed, whether exceptions are properly documented, and whether financial conflicts are influencing coverage outcomes.

HR leaders often worry that stronger formulary controls will create disruption. That concern is valid. Employees do not want to hear that a drug they have been taking is no longer preferred. HR does not want angry calls, escalations, or disruption during open enrollment.

The answer is not to avoid formulary management. The answer is to manage change with care. Members should receive advance notice, clear alternatives, access to clinical support, and a reasonable exception pathway. Most disruption can be reduced when the process is communicated early and administered consistently.

The bigger problem is that some stakeholders use “access” as a shield against accountability. They argue that formularies restrict care, create red tape, or interfere with the doctor-patient relationship. Sometimes that criticism is sincere. Other times, it is coming from parties that benefit when formularies are loose, confusing, or rebate-driven.

There are three common types of formularies employers should understand.

1. A value-based formulary prioritizes drugs based on clinical effectiveness and total net cost. This model is usually best aligned with fiduciary oversight because it asks whether the plan is paying for the right drug at the right cost for the right reason.
2. A rebate-driven formulary gives preferred placement to drugs that produce favorable rebate economics. This may lower the apparent cost on paper, but it can also favor higher list price drugs and create conflicts between plan savings and PBM revenue.
3. A hybrid formulary blends clinical value, net cost, access, and rebate considerations. This can work, but only if the employer has full transparency into the decision-making process and can verify whether preferred drugs are truly in the plan’s best interest.

My bottom line.

Use 2 percent to 3 percent of total net drug spend as the working benchmark for paid non-formulary spend, 3 percent to 5 percent as a watch zone, and anything above 5 percent as a trigger for immediate review. The public literature suggests many plans have far more leakage than that, especially when formularies are broad or rebate-driven.

Formulary compliance is not about denying care. It is about enforcing the plan’s clinical and financial intent. A self-funded employer that does not monitor non-formulary spend is not managing the pharmacy benefit. It is funding whatever the system allows through. That is not oversight. That is trust without verification, and in pharmacy benefits, that is expensive.

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.

Self-funded employers often face a difficult tradeoff in pharmacy benefit management. They can reduce unnecessary pharmacy spend or limit member disruption. On the surface, avoiding disruption feels like the safer path. HR teams do not want employees frustrated at the pharmacy counter, calling about medication changes, or asking why a drug that worked yesterday now requires a different process today.

That concern is real. But it can also become expensive. In many pharmacy plans, meaningful savings are available through better formulary management, stronger utilization management, and a more disciplined approach to generic and therapeutic alternatives. The challenge is that those savings often require some level of change for a small portion of members.

The Concern: Member Disruption

When a plan moves from a loose formulary to a more carefully managed one, some members may be affected. A member may need to switch from a brand drug to a generic equivalent. Another may need to move to a lower cost therapeutic alternative. Others may go through prior authorization, step therapy, or an exception review.

That creates anxiety for HR, and understandably so. HR teams often hear the complaints, even when the clinical and financial rationale is sound. No one wants a benefit change to feel like a takeaway, especially when employees are dealing with medications they rely on. But the question should not be, “Will there be any disruption?” A better question is, “Is the disruption clinically appropriate, financially justified, and properly supported?”

Reckless vs. Responsible Disruption

There is a big difference between reckless disruption and responsible disruption. Reckless disruption happens when members are forced through confusing changes without support, communication, or clinical review. That creates frustration and can harm trust. Responsible disruption looks different. It includes:

• Advance member notice before changes take effect
• Prescriber outreach when therapy changes may be needed
• Clear therapeutic alternatives when clinically appropriate
• Exception protocols for members with legitimate clinical needs
• Pharmacist support for members who need help navigating the change

That is not disruption for the sake of savings. That is fiduciary plan management.

The Fiduciary Issue

Self-funded employers have a duty to manage plan assets carefully. Every unnecessary dollar spent on an avoidable high-cost medication is a dollar that cannot be used for wages, benefits, reserves, or other priorities. When lower-cost alternatives are clinically appropriate, ignoring them is not member advocacy. It is poor stewardship.

Take a simple generic dispensing rate example. Assume a self-funded plan spends $10 million annually on pharmacy claims and has an 80% generic dispensing rate. If stronger formulary management, utilization management, and member support can move that plan to a 90% generic dispensing rate, the plan gains ten percentage points of improvement.

If each one point increase in generic dispensing rate produces an estimated 4% gross savings, the math is hard to ignore. A ten point improvement would represent an estimated 40% gross savings opportunity. On a $10 million annual pharmacy spend, that equals approximately $4 million in potential gross savings.

That does not mean every plan will capture the full amount. Savings depend on the drug mix, brand utilization, specialty exposure, rebates, member behavior, prescriber cooperation, and how well the transition is managed. But the example makes the fiduciary point clear. Even modest improvements in generic dispensing can create major financial consequences for a self-funded employer.

A low generic dispensing rate, high non-formulary spend, or excessive use of non-preferred brands can signal that the plan is paying more than necessary. These patterns do not always mean care is better. Often, they mean the formulary is not being managed tightly enough, the incumbent PBM has not applied sufficient controls, or the plan sponsor has not been given a clear picture of the tradeoffs.

The Cost of Doing Nothing

HR teams often feel caught between two pressures: controlling pharmacy costs and avoiding employee complaints. That tension is real. But avoiding every difficult conversation is not a strategy. It usually means the plan is allowing historical prescribing patterns, manufacturer influence, or PBM economics to drive decisions.

Before implementing any major formulary or utilization management change, the affected member population should be reviewed carefully. Some members may have direct generic equivalents available. Others may have lower-cost therapeutic alternatives. Some cases may require clinical review. A smaller group may need more hands-on support to avoid confusion or gaps in therapy.

This is where many employers make the wrong comparison. They compare the discomfort of change against the comfort of doing nothing. But doing nothing has a cost, and in pharmacy benefits, that cost can be substantial.

The Better Standard

The purpose of a well-managed pharmacy benefit is not to keep everything exactly as it is. It is to protect members while protecting the plan. Sometimes that means change. Sometimes it means telling a member, “There is a clinically appropriate alternative, and the plan will support you through the transition.”

That message is not anti-member. It is honest. Most employees do not know whether their medication is preferred, non-preferred, non-formulary, or clinically replaceable. They only know what their doctor prescribed and what they pay at the pharmacy counter. It is the plan’s responsibility, with the right pharmacy benefit administrator, to create a structure that helps members get appropriate care without wasting plan dollars.

Disruption should be minimized, not worshipped. The better goal is not zero disruption. The better goal is the right disruption, for the right reasons, with the right support. For self-funded employers, that distinction can be worth millions.

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.

A pharmacy claim can look clean and still be wrong. That is the uncomfortable truth employers need to understand. A drug can pass through adjudication, meet the plan’s coverage rules, generate a paid claim, and still fail the most important test: whether that medication is appropriate, necessary, and likely to work for the patient.

Clinical rigor is the discipline that closes that gap.

Over the past 10 years, while onboarding new clients, our team has identified dozens of situations where drugs costing more than $100,000, per year, had already been adjudicated and approved, only for genetic testing to later reveal they were unlikely to work for the patient. That is not a minor oversight. It is a break in the evidence trail before plan assets were spent.

The key elements include:

• Pharmacogenomics gives employers and fiduciaries another layer of clinical protection. It can help determine whether a patient’s genetic profile makes a drug ineffective, unsafe, or less appropriate than another therapy. Pharmacogenomics is not relevant to every drug or every patient, but where it is clinically indicated, it should be part of the review before a high-cost approval. For high-cost therapies, especially specialty medications, this should not be treated as academic medicine. It is practical plan governance.
• Medication therapy management is just as important. This becomes even more critical when plans use international mail programs or when claims adjudicate outside the normal electronic workflow. When a claim bypasses the standard drug utilization review process, the plan may also lose basic clinical safeguards, including checks for duplicate therapy, drug-drug interactions, contraindications, and dosing concerns. A lower unit cost is not a bargain if clinical oversight is stripped out of the transaction.
• Utilization management must also carry real clinical weight. Prior authorization should not be a paperwork ritual. A credible PA process should review FDA labeling, clinical trial checkpoints, patient selection criteria, diagnosis confirmation, contraindications, and prior therapy history. The question should not be, “Was the form completed?” The question should be, “Does this patient match the evidence that supports use of this drug?”
• Formulary management is where fiduciary discipline often gets tested. Employers should know the difference between a rebate-driven formulary, which may favor drugs that improve PBM economics and a value-based formulary, which weighs clinical effectiveness, safety, total net cost, and patient outcomes. But even a sound formulary can be undermined if a conflict-free P&T committee’s evidence-based decisions are bypassed by rubber stamped prior authorizations. The PA process should defend the formulary’s clinical logic, not quietly dismantle it.
• Medication adherence is the last piece, and it is often the most measurable. Plans should track proportion of days covered, or PDC, to understand whether members are actually taking their medications as prescribed. Poor adherence turns good prescribing into poor outcomes and can drive avoidable medical spend.

Clinical rigor is not about slowing care down.

It is about refusing to let plan dollars move faster than the evidence. For employers with fiduciary responsibilities, that distinction matters. A pharmacy benefit should not merely pay claims. It should prove, before and after payment, that the therapy was worth funding.

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.

A pharmacy claim can look clean and still be wrong. That is the uncomfortable truth employers need to understand. A drug can pass through adjudication, meet the plan’s coverage rules, generate a paid claim, and still fail the most important test: whether that medication is appropriate, necessary, and likely to work for the patient.

Clinical rigor is the discipline that closes that gap.

Over the past 10 years, while onboarding new clients, our team has identified dozens of situations where drugs costing more than $100,000, per year, had already been adjudicated and approved, only for genetic testing to later reveal they were unlikely to work for the patient. That is not a minor oversight. It is a break in the evidence trail before plan assets were spent.

The key elements include:

• Pharmacogenomics gives employers and fiduciaries another layer of clinical protection. It can help determine whether a patient’s genetic profile makes a drug ineffective, unsafe, or less appropriate than another therapy. Pharmacogenomics is not relevant to every drug or every patient, but where it is clinically indicated, it should be part of the review before a high-cost approval. For high-cost therapies, especially specialty medications, this should not be treated as academic medicine. It is practical plan governance.
• Medication therapy management is just as important. This becomes even more critical when plans use international mail programs or when claims adjudicate outside the normal electronic workflow. When a claim bypasses the standard drug utilization review process, the plan may also lose basic clinical safeguards, including checks for duplicate therapy, drug-drug interactions, contraindications, and dosing concerns. A lower unit cost is not a bargain if clinical oversight is stripped out of the transaction.
• Utilization management must also carry real clinical weight. Prior authorization should not be a paperwork ritual. A credible PA process should review FDA labeling, clinical trial checkpoints, patient selection criteria, diagnosis confirmation, contraindications, and prior therapy history. The question should not be, “Was the form completed?” The question should be, “Does this patient match the evidence that supports use of this drug?”
• Formulary management is where fiduciary discipline often gets tested. Employers should know the difference between a rebate-driven formulary, which may favor drugs that improve PBM economics and a value-based formulary, which weighs clinical effectiveness, safety, total net cost, and patient outcomes. But even a sound formulary can be undermined if a conflict-free P&T committee’s evidence-based decisions are bypassed by rubber stamped prior authorizations. The PA process should defend the formulary’s clinical logic, not quietly dismantle it.
• Medication adherence is the last piece, and it is often the most measurable. Plans should track proportion of days covered, or PDC, to understand whether members are actually taking their medications as prescribed. Poor adherence turns good prescribing into poor outcomes and can drive avoidable medical spend.

Clinical rigor is not about slowing care down.

It is about refusing to let plan dollars move faster than the evidence. For employers with fiduciary responsibilities, that distinction matters. A pharmacy benefit should not merely pay claims. It should prove, before and after payment, that the therapy was worth funding.

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.

Self-funded employers often face a difficult tradeoff in pharmacy benefit management. They can reduce unnecessary pharmacy spend or limit member disruption. On the surface, avoiding disruption feels like the safer path. HR teams do not want employees frustrated at the pharmacy counter, calling about medication changes, or asking why a drug that worked yesterday now requires a different process today.

That concern is real. But it can also become expensive. In many pharmacy plans, meaningful savings are available through better formulary management, stronger utilization management, and a more disciplined approach to generic and therapeutic alternatives. The challenge is that those savings often require some level of change for a small portion of members.

The Concern: Member Disruption

When a plan moves from a loose formulary to a more carefully managed one, some members may be affected. A member may need to switch from a brand drug to a generic equivalent. Another may need to move to a lower-cost therapeutic alternative. Others may go through prior authorization, step therapy, or an exception review.

That creates anxiety for HR, and understandably so. HR teams often hear the complaints, even when the clinical and financial rationale is sound. No one wants a benefit change to feel like a takeaway, especially when employees are dealing with medications they rely on. But the question should not be, “Will there be any disruption?” A better question is, “Is the disruption clinically appropriate, financially justified, and properly supported?”

Reckless vs. Responsible Disruption

There is a big difference between reckless disruption and responsible disruption. Reckless disruption happens when members are forced through confusing changes without support, communication, or clinical review. That creates frustration and can harm trust. Responsible disruption looks different. It includes:

• Advance member notice before changes take effect
• Prescriber outreach when therapy changes may be needed
• Clear therapeutic alternatives when clinically appropriate
• Exception protocols for members with legitimate clinical needs
• Pharmacist support for members who need help navigating the change

That is not disruption for the sake of savings. That is fiduciary plan management.

I recently asked ChatGPT to score our pharmacy benefit administrator (PBA) services agreement on how much control and transparency it gives self-funded employers. Here was the prompt: “Act as an ERISA attorney and pharmacy benefits expert. Score the attached contract on a scale of 1 to 10 on how much control and transparency it provides to self-funded employers.” The score came back 9.6 out of 10. Skeptical? Good. You should be.

In pharmacy benefits, big transparency claims deserve pressure testing. So call my bluff. Ask for the agreement. Read the audit clause. Review the rebate language. Look at who controls the formulary, specialty pharmacy arrangements, network strategy, data access, and plan economics.

Then do the same with your current PBM or PBA agreement. Use the same prompt. Pressure test the contract you already have in place. The answer may show whether your agreement gives the plan sponsor enforceable control, or whether it relies too heavily on vendor promises. What surprised me was not the score itself. It was how much the score changed when the contract posture changed.

Prompt: Act as an ERISA attorney and pharmacy benefits expert. Score the attached contract on a scale of 1 to 10 on how much control and transparency it provides to self-funded employers.

The existing version, built around a fiduciary pharmacy benefit administrator model, scored 9.6 out of 10. The reason was straightforward. The agreement gave the employer final authority over plan design, formulary, utilization management, pharmacy network decisions, manufacturer contracting, rebate strategy, and coverage policy. TransparentRx did not have discretionary authority over those decisions. It also included broad audit rights, pass-through economics, specialty compensation disclosure, and client ownership of plan-attributable rebates, credits, discounts, fees, and other financial benefits.

Then I asked a different question: what happens if the fiduciary language is removed and the contract describes the company as a pharmacy benefit manager instead of an administrator?

The score dropped to roughly 7.2 out of 10. That is not a cosmetic change. It affects money, oversight, and CAA documentation. Contract posture has financial and compliance consequences. If an agreement reads like a conventional PBM contract, the employer may lose leverage over the very items that determine whether the plan is truly being managed in its best interest:

• Rebate strategy and whether all plan-attributable rebates are disclosed, reconciled, and returned.
• Specialty pharmacy economics, including margins, referral arrangements, data fees, service fees, and affiliate relationships.
• Audit access to claims-level data, pharmacy reimbursement records, MAC list application, manufacturer payments, aggregator records, and subcontractor compensation.
• CAA RxDC reporting at the plan level, not just the vendor’s aggregate book of business. Aggregate reporting may help a vendor complete a filing, but it does not give the employer enough visibility to verify its own prescription drug spend, rebates, high-cost drugs, top drugs, member cost-sharing, or vendor compensation. Plan-level reporting ties the data back to the employer’s actual claims experience, which is what fiduciaries need for cost oversight, renewal decisions, rebate reconciliation, and CAA documentation.
• Fiduciary documentation. A weaker contract can make it harder for the plan sponsor to show it had the contractual right to obtain, review, and verify the financial data behind pharmacy spend.

Transparency is not meaningless. It is essential, but it has to be enforceable.

A vendor can say it is transparent, but the contract must give the plan sponsor the right to obtain, audit, reconcile, and use the data needed to manage the plan, verify financial performance, and meet reporting obligations. In pharmacy benefits, transparency without contractual rights is just a talking point.

Here is the scorecard under the existing service agreement:

The lesson is simple: contract labels matter, but contract authority matters more. 

A self-funded employer should know exactly where control sits. That means knowing who controls the plan, formulary, rebate strategy, and pharmacy network. It also means knowing who owns the data, who can audit the financial flows, and who receives every dollar tied to the plan.

Brokers, consultants, and Benefit Directors should not stop at “transparent PBM” language. Ask for the agreement. Read the audit clause. Review rebate ownership. Check specialty compensation. Confirm who has final decision-making authority. Then ask one direct question: does this agreement give the plan sponsor enforceable control, or does it leave the employer relying on vendor promises?

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.

Buying pharmacy benefits is no longer a routine procurement exercise. For brokers, consultants, CFOs, and HR leaders, PBM oversight now sits squarely in the risk management category. The wrong contract, the wrong data rights, or the wrong internal assumptions can cost a plan millions. Here are six non-negotiables every pharmacy benefits purchaser should demand.

Knowledgeable staff

A prudent process starts with competent people. The fiduciary standard does not require perfection, but it does require informed decision-making. That means the employer, broker, consultant, and internal benefits team must understand how PBMs make money, how to design a pharmacy benefit, how to evaluate clinical management, how specialty drugs are priced, and where conflicts of interest appear.

The “prudent expert” requirement matters. If the plan sponsor does not have that expertise internally, it must hire it. Relying on a PBM to explain whether its own arrangement is fair is not oversight. It is delegation without control.

Vendor contract access

Purchasers need access to vendor contracts, not just summaries, assurances, or sanitized reporting. One reason is international mail order pharmacy arrangements. In some cases, drugs sourced through these channels are marked up by 2,000% or more before being passed through the benefit plan.

That kind of spread does not show up clearly in a typical PBM performance review. It is buried in related-party arrangements, subcontractor agreements, specialty pharmacy terms, or opaque purchasing structures. If the purchaser cannot see the underlying contracts, it cannot verify whether pricing is fair.

Claim data access

Access to complete, usable, plan-level claim data is no longer optional. The Department of Labor and Consolidated Appropriations Act enforcement environment will only put more pressure on plan fiduciaries in 2026 and beyond.

Plan sponsors need data that allows independent review of drug pricing, rebates, fees, specialty claims, formulary decisions, prior authorization outcomes, and pharmacy reimbursement. A PDF summary from the PBM is not enough. Purchasers need raw data rights, audit rights, and the ability to share data with independent advisors working on behalf of the plan.

Medical benefit drug claim oversight

High-cost drugs are not only paid through the pharmacy benefit. Many are billed under the medical benefit through physician offices, hospital outpatient departments, infusion centers, and specialty clinics. These claims may involve J-codes, HCPCS codes, units, modifiers, and provider markups that are difficult to monitor without the right data.

Purchasers should require access to medical drug claim data and an independent review process to evaluate pricing, units billed, site-of-care patterns, duplicate billing, and opportunities to move select drugs to lower-cost channels when appropriate. PBM oversight is incomplete if medical benefit drug spend is ignored.

Fiduciary PBM contract

There is a difference between a fiduciary PBM contract and a contract that uses friendly language like “fiduciary aligned.” Purchasers should not accept branding, slogans, or partial transparency as a substitute for enforceable fiduciary obligations.

A real fiduciary PBM contract should define who the PBM serves, how compensation is earned, what revenue must be disclosed, what must be passed through, and what happens when conflicts arise. If the PBM keeps spread pricing, hidden rebates, data fees, manufacturer payments, pharmacy network revenue, or GPO income, the contract should say so plainly.

Adequate resources

PBM oversight requires independent tools. Do not rely solely on PBM self-reporting. The plan sponsor should have its own resources to validate pricing, benchmark claims, review specialty costs, and test contract performance.

At a minimum, purchasers should have access to an independent AWP price reporting agreement or similar pricing validation resource. Without it, the plan is asking the PBM to grade its own paper.

The larger point is simple: pharmacy benefits purchasers cannot manage what they cannot see, test, or enforce. A fiduciary standard of care demands more than a competitive RFP. It demands evidence, access, expertise, and contractual accountability.

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.

The old PBM sales pitch is no longer enough. In today’s environment, cost management must be measurable, defensible, and open to inspection. With drug spend still climbing and scrutiny intensifying, plan sponsors cannot afford vague promises or half-measures. A PBM that claims to act in the client’s best interest should be able to prove it in plain view. Here are seven ways to tell whether your PBM is truly operating at maximum cost-effectiveness.

1. Rebates decrease when total cost of pharmacy care (TCoPC) decreases for new implementations.
   If a new PBM implementation lowers net drug spend, rebate yields may also decline because fewer high-cost brand claims are being dispensed. That is not a red flag. It is often evidence that the PBM is steering the plan toward lower cost alternatives. Brokers and Benefits Directors should focus on total cost of care, not rebate totals in isolation. A bigger rebate check means little if overall spend remains inflated.
2. At least 90% of generic claims are MAC’d.
   A PBM serious about controlling cost should place the overwhelming majority of generic claims under a Maximum Allowable Cost methodology. When too many generic claims fall outside MAC, the plan is exposed to unnecessary spread and inflated reimbursement. This metric gives consultants and fiduciaries a quick way to test whether the PBM is applying disciplined pricing controls where they matter most.
3. Prior authorization approval rates fall in the 50% to 60% range.
   A PA program that approves nearly everything is not managing utilization. It is rubber-stamping it. A rate in the 50% to 60% range suggests the PBM is conducting real clinical review and stopping inappropriate or avoidable spend. For Benefits Directors, that means the utilization management program is doing its job instead of serving as window dressing.
4. The PBM supports carve-outs.
   When a PBM resists carve-outs, the objections usually sound familiar: safety concerns, compliance risk, operational complexity, or disruption. Plan sponsors have heard it all. In many cases, that resistance is about preserving control and protecting revenue streams. A cost-effective PBM should be willing to support carve-outs when they create better economics or oversight for the client.
5. Generic dispensing rate is 90% or higher.
   A high GDR remains one of the clearest signs that the plan is being steered toward lower-cost therapies when clinically appropriate. It does not tell the whole story, but it is still a strong indicator of formulary discipline, prescriber engagement, and member channel management. For brokers, it is a simple metric that signals whether savings strategies are translating into actual behavior.
6. Specialty dispensing rate is 1% or lower.
   Specialty utilization drives an outsized share of pharmacy spend. A lower SDR can indicate tighter management, better site-of-care strategies, stronger prior authorization controls, and more effective biosimilar adoption. Benefits leaders should watch this closely because even small changes in specialty mix can materially affect total plan cost.
7. You can review the PBM’s vendor contracts.
   If the PBM will not let you review contracts with mail pharmacies, rebate aggregators, TPAs, PGx vendors, MTM vendors, and others, you are being asked to trust what should be verified. Transparency at this level is no longer optional. Given the current climate, PBMs must be beyond reproach in their client business affairs. Anything less should concern every fiduciary.

A PBM that truly maximizes cost-effectiveness does not hide behind talking points. It shows its work.

How We Can Work Together

Whether you’re a plan sponsor trying to get control of pharmacy spend, or a broker guiding clients through PBM decisions, education is the fastest way to improve outcomes. If you want a focused, high-value session your team can actually use, here are several ways we can work together.

Option 1: Get Certified

American College of Benefit Specialists (ACoBS) equips benefits professionals with practical knowledge across pharmacy, medical, retirement, and voluntary benefits. Organizations working with ACoBS-certified consultants gain better plan oversight, stronger vendor accountability, and more disciplined cost control. The certification signals a clear commitment to fiduciary guidance and protecting plan assets.

Option 2: Book a Webinar

A clean, educational session for employers, brokers, or TPAs. We’ll cover the most common PBM profit tactics, how to spot contract red flags, and what a fiduciary standard of care looks like in pharmacy benefits. Great for client education and thought leadership.

Option 3: Join the Virtual Roundtable

Bring your internal team (HR, Finance, and Benefits) or your broker group. I’ll lead a live discussion focused on PBM oversight, cost drivers, and what to ask your PBM right now. You’ll leave with a short action list you can use immediately.

Option 4: Get a Quote

Pharmacy benefits now rival medical spend for many plans. Yet most are still governed by contracts few have fully read and pricing models few can clearly explain. That is a fiduciary risk, not just a cost issue.

If you want lower spend, tighter oversight, and alignment you can defend in front of a board or audit committee, act with intent. Certify your team. Educate your clients. Pressure test your PBM.